The linked FDA records place Tiger Aesthetics Medical, LLC at the address listed in the PMA filings at 9779 S. Franklin Dr., Suite 300, Franklin, Wisconsin, as applicant for P070004, trade-named Sientra® Silicone Gel Breast Implants. The device is classified as a noninflatable internal silicone gel-filled breast prosthesis, Class III, under regulation number 878.3540, with the advisory committee described as General, Plastic Surgery. The original approval decision is dated March 9, 2012, and a labeling supplement decision is dated November 4, 2026. [1][2]
Documented product and classification
The PMA records identify the device generically as a silicone gel-filled breast implant prosthesis and give the trade name Sientra® Silicone Gel Breast Implants, with product code FTR and device class 3. The openFDA fields in the same filings list the device name as Prosthesis, Breast, Noninflatable, Internal, Silicone Gel-Filled, and the regulation number as 878.3540. The applicant of record on both filings is Tiger Aesthetics Medical, LLC. [1][2]
The original approval statement describes two indication categories: breast augmentation for women at least 22 years old, including revision surgery to correct or improve the result of primary augmentation, and breast reconstruction, including primary reconstruction to replace breast tissue removed due to cancer or trauma or that failed to develop properly, plus revision surgery for primary reconstruction. [2]
Filing history in the linked FDA records
P070004 was received January 22, 2007, and approved March 9, 2012, with decision code APPR and docket number 12M-0250; the expedited review flag is recorded as N. The filing carries no supplement number or supplement type. [2]
Supplement S049 was received October 5, 2026, and approved November 4, 2026, under decision code APPR. It is recorded as a Special (Immediate Track) supplement with the reason Labeling Change - Indications/instructions/shelf life/tradename, and the expedited review flag is N. [1]
The approval order for S049 states that CDRH completed review of the PMA supplement, which requested labeling updates to enhance safety in the use of the implants, and that the submission meets the criteria in 21 CFR 814.39(d)(2) for a Special PMA Supplement - Changes Being Effected. [1]
Collection scope and post-approval obligations
The supplied collection contains two linked PMA records, both with decision APPR; the record sample of two entries also shows two APPR decisions. These counts describe the supplied filings as of the snapshot date and are not a measure of total company portfolio, sales or safety performance. No recall records appear in the supplied sample. [1][2]
The Summary of Safety and Effectiveness Data states that Sientra must conduct non-PAS Device Explant Analyses for all Sientra Silicone Gel Breast Implants retrieved in the commercial setting outside the post-approval studies, reporting results annually in PMA Annual Reports, and that the manufacturing facility was inspected and found in compliance with the Quality System regulation at 21 CFR 820. [9]
Brand context and attribution
Tiger Aesthetics company pages describe the Sientra silicone gel implants with features including a proprietary flat back, a High Strength Cohesive Gel (HSC/HSC+) and gel-shell integration; these are the publisher's product descriptions, not independently verified findings. The same pages state that Tiger Aesthetics Medical, LLC has acquired Suneva and its Bellafill®, Silhouette Instalift™ and Amplifine PRP products. [7][8]
The SSED lists the applicant's name and address as Sientra, Inc., 6769 Hollister Ave, Suite 201, Santa Barbara, California 93117, reflecting the applicant of record at the time of the original approval rather than a current headquarters designation. [9]
